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Summary
Objective: To investigate the relationships between serum and urinary molecular markers (MM) used to monitor osteoarthritis.
Design: Forty osteoarthritis patients had blood and urine collected at baseline and 1, 3, 6 and 12 months later. Specimens from 20 controls
were obtained twice at a one month interval. The concentration of 14 different markers was determined at each time point and the data were
analyzed by statistical methodology.
Results: The markers could be divided by the method of principal components analysis into five clusters of related markers: inflammation
markers (C-reactive protein, tumor necrosis receptor type I and tumor necrosis receptor type II, interleukin 6, eosinophilic cationic protein),
bone markers (bone sialoprotein, hydroxylysyl pyridinoline, lysyl pyridinoline), putative markers of cartilage anabolism (carboxypropeptide of
type II procollagen, hyaluronan, epitope 846) and catabolism (keratan sulfate, cartilage oligomeric matrix protein), and transforming growth
factor beta. Three markers (tumor necrosis factor receptor II, cartilage oligomeric matrix protein and epitope 846) from independent clusters
discriminated osteoarthritis patients from controls. Inflammation was not a confounding factor in measurement, but a recognizable
distinguishing factor in osteoarthritis.
Conclusions: The markers separated into rational groups on the basis of their covariance, a finding with independent biochemical support.
The covariance of markers from the same cluster suggests the use of a representative marker from the cluster to reflect changes in
osteoarthritis. If multiple markers are being measured within a single cluster, then the use of a weighted cluster ‘factor’ may be preferable
to the separate use of individual markers. © 2000 OsteoArthritis Research Society International
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Osteoarthritis (OA) of the knee occurs with increasing
frequency and severity with age. It is generally character-
ized by joint space narrowing on X-ray, knee pain, and a
loss of joint function. Except for OA arising from injury to the
knee, it is often difficult to clearly distinguish the clinical
disease from a slow deterioration of the cartilage with age.
Even though this is a disease afflicting a significant portion
of the population, its evolution over decades has made
clinical studies difficult. Changes in disease status over a
single year are often small and difficult to quantitate. Under
such circumstances, the identification, if possible, of
molecular markers in easily sampled body fluids such as
blood or urine, which reflect differences in disease progres-
sion rates, would greatly facilitate clinical studies.1 A good
molecular marker should define differences between OA180patients and normal individuals. It should also define
changes in patient clinical status over time.
A number of candidate molecular markers (MM) have
been identified.2 The MM that have so far been examined
can be classified into two types, skeletal and inflammation
markers. Skeletal markers are related to changes in carti-
lage or bone metabolism: keratan sulfate (KS),3–5 the
carboxypropeptide of type II procollagen (CPII),6,7 bone
sialoprotein (BSP),8,9 cartilage oligomeric matrix protein
(COMP),7,9,10 aggrecan fetal epitope (epitope 846),7,11,12
hydroxylysyl pyridinoline (HP) and lysyl pyridinoline
(LP).13–15 Disease markers are related to inflammation:
C-reactive protein (CRP),16 tumor necrosis factor receptor
type I (TNF-RI) and tumor necrosis factor receptor type II
(TNF-RII), interleukin 6 (IL-6),17 hyaluronan (HA)18–20
transforming growth factor beta (TGF), and eosinophil
cationic protein (ECP).21–23
Molecular markers of skeletal metabolism and inflam-
mation from easily sampled body fluids were examined for
differentiating individuals with OA from control individuals.
Markers that have sufficient discriminatory power at base-
line to distinguish between OA patients and normal individ-
uals are candidates for monitoring changes in disease
status. In addition, statistical methodology was applied to
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group markers into related clusters. This allows the deter-
mination of which markers give independent information
and which markers should be grouped together as related
markers. Such a comprehensive analysis has never
previously been attempted.Patients and methods
PATIENTS
Sera and 24 h urines were collected from 34 female and
five male patients with a diagnosis of idiopathic OA and
involvement of at least one large joint (knee or hip) of
radiological grade 1–3 by ACR OA criteria.24,25 Their ages
ranged from 45 to 61 with a mean age of 57 years. Each
patient was removed from prior therapy (NSAID) for one
week prior to the baseline visit. Five mls of blood and a 24 h
urine specimen were taken at baseline. After the baseline
visit, patients were placed on piroxicam 20 mg/day, and
blood and urine specimens collected at visits 1, 3, 6, and 12
months later. A control cohort of 13 females and eight
males (N) who were without joint pain (age range 45 to 63
with a mean of 50 years) were sampled twice at a one
month interval. Blood as serum and urine were aliquoted
and stored at −72°C until assayed. All samples for each
assay were measured at one time in order to minimize
variability.ASSAYS
KS was measured using antibody AN9P1 as the F(ab′)2
in a competitive radioimmunoassay (RIA).5 CP-II was also
measured by RIA;7 BSP was measured by ELISA;8 COMP
was measured using rabbit polyclonal antibody;10 epitope
846 was measured as described.5 Commercial ELISAs
were used to measure CRP (Hemagen CRP Kit, Hemagen
Diagnostics, Inc., Waltham, MA); TNF-RI (QuantikineY
Human sTNF RI Immunoassay), TNF-RII (QuantikineY
Human sTNF RII Immunoassay), IL-6 (High Sensitivity Hu-
man IL-6 Immunoassay) and TGF1 (QuantikineY Human
TGF1 Immunoassay) (R&D Systems, Minneapolis,
MN); ECP and HA (Pharmacia Diagnostics AB, Uppsala,
Sweden).
Hydroxylysyl pyridinoline (HP) and lysyl pyridinoline (LP)
were analyzed after hydrolysis of urinary protein and sep-
aration of the cross-links on HPLC using a fluorescence
detector.13 Creatinine was determined for each urine on a
clinical Boehringer Mannheim Hitachi 717 analyzer using
a modified Jaffe reaction and the values for HP and LP
divided by the creatinine concentration.STATISTICAL PROCODURES
Statistical analyses were carried out with software from
SAS (SAS Institute, Cary, NC 27512) and Statistica
(StatSoft Inc., 2325 E. 13th St., Tulsa, OK 74104). The
control and osteoarthritis groups were compared at base-
line by Wilcoxon rank sum statistics, and by calculation of
geometric means and 95% population confidence bounds.
For all statistical tests that require normal distributions, the
use of logarithms of all independent variables except age
was necessary. Possible associations in data at baseline
were explored by SAS Proc Factor, using principal com-ponents analysis with orthomax factor rotation and by
Spearman rank order correlation.ResultsDIFFERENCES AMONG MOLECULAR MARKERS, OA PATIENTS VS.
HEALTHY INDIVIDUALS
In order to learn whether any of the MM are suitable for
monitoring disease status in OA clinical trials, it was first
determined which of the MM were statistically different
between OA patients and healthy controls. The baseline
visits of the control population were compared with the
baseline visits of the OA patients taken after a one week
washout without drug. The data for each of the 14 MM are
summarized in Table I. The values for the MM generally
were not normally distributed, and it was necessary to
transform the data to logarithms to obtain approximately
normal distributions. Therefore, geometric means were
determined, and 95% ranges rather than standard devi-
ations were calculated. The values were compared using
Wilcoxon Rank Sum Scores, which do not depend on
distributions.
BSP, hyaluronan, C-propeptide of type II collagen, and
TGF1 all failed to distinguish the OA from the control
group. The ten other MM (TNF-RI, TNF-RII, CRP, ECP,
IL-6, KS, HP/Cre, LP/Cre, COMP, epitope 846) showed
highly significant differences between controls and OA
patients. In all cases, the range of the control and the OA
populations overlapped.DISCRIMINANT ANALYSIS
Discriminant analysis was used to further investigate
which of the markers (plus age), singly or in combination,
were best able to distinguish between OA patients and
control individuals. Preliminary results have been
reported.26 Stepwise backward elimination of non-
informative variables, with cross-validation at each step,
was used to arrive at an optimal linear model. Linear and
kernel-based discriminant methods both yielded compar-
able results. The final model contained TNF RII, COMP,
epitope 846, and age as significant (P≤0.01) discriminating
variables. However, use of TNF RII alone provided reason-
ably good discrimination, with correct classification of 80%
of controls and 86% of OA patients. In the factor analysis
(see below), TNF RII, COMP and epitope 846 were not
correlated with each other.LOGISTIC REGRESSION
To aid in understanding the ability of markers to
distinguish between OA patients and control individuals,
logistic regression was carried out, with disease status (0 or
1) as the dependent variable, and TNF RII and COMP as
the predictor variables. Because of the limitation of the
graphical display to two dimensions, epitope 846 was not
included. In the graphical display (Fig. 1), each point
represents one patient, either OA or control, plotted accord-
ing to the values of the predictor variables. Existence of OA
is likely (P≥0.90) in the upper region of the graph, and
is unlikely (P≤0.10) in the lower region. The contours
represent equal (P=0.10) intervals of predicted disease
status in the logistic model. The effectiveness of the
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readily observed in the display.PRINCIPAL COMPONENTS ANALYSIS
Factor analysis by the method of principal components
was carried out to determine which MM were significantly
correlated with one another. Disease, except insofar as it
contributes to a broader range of values for the MM, was
not involved in this determination, and both control and OA
individuals were grouped together. Age of subject was also
included as a variable. The five principal components that
account for 72% of the variance summarize the relation-
ships. The principal components matrix was rotated by the
orthomax method, and the loading coefficients of each ofthe 15 variables in each of the five principal components
are reported (Table II). The primary contributors to each
principal component are indicated in bold-face. Although
only the results at baseline are reported, the same marker
associations and groupings in clusters were found at all
time points, i.e., baseline, 1, 3, 6 and 12 months.
Factor 1 accounted for the largest portion of the variance
and was comprised of markers of inflammation (IL-6, CRP,
TNF RI, TNF RII, and ECP). There was an association of
less significance between increasing values for the inflam-
mation markers and increasing age. This latter association
has been previously reported for CRP in the general
population.
Factor 2 was comprised of markers considered to be
primarily of bone origin (HP, LP and BSP), although a
portion of HP also arises from cartilage.
Four of the remaining six MM are products of cartilage
(epitope 846, CPII, COMP, KS) and they divided into two
factors, Factor 3 (epitope 846, HA, CPII), and Factor 4
(COMP, KS). HA, although found in cartilage, is far more
abundant in synovial fluid, yet it aligned with Factor 3.
TGF1 is a growth factor without any known relationship to
any of the other MM. It is not surprising that it segregated
into a separate factor, Factor 5.Table I
Comparison of molecular markers between osteoarthritis patients and normal individuals*
Marker† Units Normal
geometric
mean
Confidence
limits
95%
N OA
geometric
mean
Confidence
limits
95%
N N vs OA
P-value
BSP ng/ml 98.7 51.7–188 21 93.3 44.7–195 34 0.8016
IL-6 pg/ml 1.67 0.51–5.46 21 2.99 0.75–11.9 39 0.0043
Epitope 846 g/ml 0.087 0.027–0.28 21 0.05 0.016–0.156 36 0.0006
KS g/ml 2.18 1.02–4.66 21 1.55 0.88–2.75 36 0.0008
CPII ng/ml 24.01 18.9–30.4 21 22.95 18.5–28.5 37 0.1857
HA ng/ml 43.24 18.5–101 21 49.85 10.2–244 37 0.2240
ECP ng/ml 9.13 3.28–25.4 21 13.83 4.64–41.3 36 0.0089
CRP g/ml 1.64 0.34–7.97 20 5.03 0.58–43.8 39 0.0004
COMP g/ml 10.72 7.19–16.0 21 8.84 5.45–14.3 39 0.0011
HP/Cre nM/mM‡ 31.4 22.1–44.5 21 43.3 23.4–79.8 37 0.0001
LP/Cre nM/mM 10.5 6.0–18.4 21 14.0 5.88–33.4 37 0.0040
TNF RI pg/ml 995 568–1745 20 1449 834–2517 37 0.0001
TNF RII pg/ml 1569 897–2747 20 2463 1424–4261 37 0.0001
TGF1 ng/ml 47.0 30.1–73.5 20 41.5 23.8–72.3 36 0.1440
*For each variable, the log10 of the parameter was taken to convert the numbers into a normal distribution.
Statistical significance between OA and normal populations was determined using the Wilcoxon Rank test.
Geometric means and confidence bounds for 95% of the population are given rather than standard deviations
because of the lack of normality of the untransformed variables.
†Marker abbreviations: BSP, bone sialoprotein; IL-6, interleukin 6; epitope 846, aggrecan fetal epitope 846;.KS,
keratan sulfate; CPII, C-propeptide of type II collagen; HA, hyaluronan; ECP, eosinophil cationic protein; CRP, C-
reactive protein; COMP, cartilage oligomeric protein; HP/Cre, hydroxylysyl pyridinoline/creatinine; LP/Cre, lysyl
pyridinoline/creatinine; TNF RI; tumor necrosis receptor type I; TNF R2, tumor necrosis factor receptor type II;
TGF1, transforming growth factor beta1.Fig. 1. Discrimination of OA patients from controls using TNF
receptor II and COMP. Logistic regression: Probability {OA}=
exp{A+B*X+C*Y}/(1+exp{A+B*X+C*Y}), where A= −6.372,
B= −0.456, X=COMP, C=0.00613, Y=TNF RII and the contour
lines=intervals of P=0.10 of predicted OA in the logistic model.
=Normal, =OA.Discussion
Fourteen MM that might be related to the status or
progression of OA were measured. Typically, when we
compared our values to those in the literature, there was
close agreement with values for the control population and
the OA population only when the same measurement
methodology was used. The largest disagreements were
in cases where different monoclonal antibodies or, as
importantly, different standards were used as the basis for
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Principal component analysis coefficients* isolation of independent factors†
Molecular
marker‡
Factor 1§ Factor 2 Factor 3 Factor 4 Factor 5
IL6 0.879 −0.003 −0.092 0.001 0.057
CRP 0.802 0.270 −0.114 −0.072 0.087
TNFRI 0.795 0.306 0.067 −0.106 −0.184
TNFRII 0.748 0.344 0.151 −0.057 −0.312
ECP 0.663 −0.186 0.133 −0.134 0.163
LP/Cre 0.138 0.928 0.080 0.003 −0.047
HP/Cre 0.290 0.903 0.007 −0.135 −0.075
BSP −0.232 0.531 −0.125 0.415 0.250
Epitope 846 −0.159 −0.131 0.711 0.298 0.050
HA 0.273 0.370 0.646 −0.032 −0.092
Age 0.462 0.078 0.606 −0.307 −0.147
CPII −0.223 −0.093 0.568 0.124 0.446
COMP 0.092 0.032 0.058 0.846 0.194
KS −0.336 −0.103 0.157 0.704 −0.196
TGF1 0.076 −0.005 0.011 0.045 0.882
Variance due to Factor¶ 3.69 2.46 1.73 1.64 1.32
*Values from normal and OA individuals were utilized to determine the correlation matrix. Disease was not
considered a variable.
†Matrix rotation and determination of the number of factors were carried out in SAS with the orthomax software
and the requirement that the eigenvalues must be greater than one for significance. Five factors were found.
‡The abbreviations for each marker are given in Table I.
§The primary components in each Factor are shown in bold.
¶The five factors together account for 72% of the total variance.the assay, for example, the keratan sulfate measurements
using monoclonal antibody AN9P1 or 7D4 or the TNF Type
II receptor using the R & D or the Medgenix kits. In one
case, IL-6, our controls suggested that our lower values
were a more accurate measure. However, in other cases,
there were no simple explanations; even measurements
made in the same laboratory with the same methodology
can differ in different studies. The differences were greater
with ELISA methods than with biochemical methods (HP,
LP). In addition to differences in the study population,
the extent of color development with a particular set of
reagents and the lack of universal standards may contrib-
ute to these literature differences. For these reasons, all
samples were assayed at the same time with the same set
of reagents. This includes not only the baseline control
and OA specimens reported here, but all patient visits.
While this does not eliminate inter-laboratory differences, it
minimizes variability within the study.
Age was included as an independent variable in all
analyses, in order to capture possible interactions between
age and the markers in distinguishing between control and
OA subjects. Even though the control and OA populations
were not perfectly age-matched, this approach was con-
sidered better than collecting an additional set of controls
and determining values in a separate set of measurements.
Only two of the 14 markers were found to have a significant
age dependency when regressed on age and disease:
epitope 846 (P=0.02) and HA (P=0.006).
Among the MM, the inflammatory MM gave the largest
separation of OA and control individuals. Yet none of the
inflammatory MM showed changes of comparable magni-
tude to RA. For example, in the control population CRP is
around 1 g/mL. In the OA population, CRP is elevated to
around 5 g/mL. Sharif et al.27 have published comparable
findings. In RA, the CRP value may be elevated from 20 to
100 g/mL or more, and it has been found to be a useful
measure of disease activity and therapy.16 Moreover, the
inflammatory MM are nonspecific measures of diseasechange; they are elevated in many diseases. Thus their
elevation becomes significant only when a primary diag-
nosis of OA is made and other possible confounding clinical
conditions have been excluded.
The most statistically significant elevation was found for
TNF-RII. It along with COMP, epitope 846 and age permit
placement of approximately 90% of both the OA and the
controls into the correct diagnosis. Thus the best discrimi-
nation was found when one marker from each of three
independent clusters was used. However, in spite of stat-
istically significant differences in skeletal markers between
the group of OA patients and the group of controls, the
overlap of patients and controls thwarts the utility of a single
skeletal marker to reliably categorize individuals.
The failure to find a significant difference in HA between
normal and OA is dependent on our choice of statistical
methodology. Because our HA values did not show a
normal distribution, a log transformation of the variables
was carried out before statistical tests were applied. If
we had used a standard t-test on the arithmetic means,
controls=42.8 vs. OA=66.8 (a statistically invalid pro-
cedure with our data set), we too would have found, like the
literature, a significant difference for HA between control
and OA. Moreover, the highly significant age dependency
of HA values must be taken into account in any analysis of
HA for monitoring OA.
The main role for principal components analysis in
experimental science is for hypothesis generation. By com-
puting the complete correlation matrix, secondary corre-
lations that occur when multiple correlations are done
pairwise are removed. By determining which MM are
associated (independent of disease), mechanistic linkages
can be suggested. With the exceptions of HA, our analysis
sorted the MM into independent factors consistent with
known biochemical relationships. Thus the clustering of the
inflammation MM together has a strong mechanistic basis.
The correlation between IL-6 and CRP in man is strong,16
anti-IL-6 antibodies dramatically lower CRP levels,28,29 and
184 I. G. Otterness et al.: Markers for OA: segregation into clustersIL-6 elevation has been correlated with TNF.30 The exo-
cytosis of ECP by eosinophils has been taken as a
measure of inflammation in rheumatoid arthritis.22,23 The
shedding of TNF R occurs during exposure to IL-1, TNF,
PDGF and IGF1.31,32
The most interesting outcome of principal components
analysis was the segregation of structural MM into factors
2, 3 and 4. This segregation appears to have a biochemical
basis: factor 2 is associated with bone markers, factor 3 is
associated with putative synthetic markers of cartilage
assembly, and factor 4 is associated with putative markers
of cartilage degradation. Thus in this case, the associ-
ation of MM into factors seems to be a valid hypothesis
generation process.
Because we did not X-ray our control population, it is
possible that some of the controls may have had asympto-
matic OA. Such an occurrence would not affect the out-
come of our factor analysis. It depends only on whether
markers change in tandem or not—controls and OA
patients are lumped together in the analysis. It could,
however, potentially cause us to underestimate the ability
of skeletal markers to differentiate between controls and
OA patients.
The principal components of factor 2, BSP, LP and HP,
arise principally from bone, although HP also has a carti-
lage component in it. We used two statistical approaches to
isolate the cartilage component and found by both that
cartilage component of HP was stably associated with the
inflammation markers (Appendix). This leads to the hypoth-
esis that crosslink loss from cartilage is related to the
degree of inflammation in OA; it is only weakly associated
with changes in degradation markers that are based on
normal cartilage turnover.
The concentrations in blood of TGF1 were uncorrelated
with any of the other MM. This implies that if TGF1 plays
a role in OA, it does not do so in a way that leads to an
association with either the skeletal or inflammation markers
we measured.Conclusions
Our results confirm that inflammation in OA is readily
measurable. Markers such as CRP and TNF type II
receptor are elevated although much more modestly than
in RA or other inflammatory diseases. The statistical
independence of the bone, cartilage catabolism and
anabolism, and TGF1 clusters from the inflammation
cluster suggests that changes in these markers are
independent of inflammation. The magnitude of change in
the skeletal markers was disappointing in these cross-
sectional patients. It augurs poorly for their utility in the clinic
and suggests that better markers need to be found. Finally,
the segregation of markers into different independent clus-
ters suggests that clinical correlations should be carried out
using the independent clusters rather than the individual
covariant markers. However, the use of a single represen-
tative marker from each cluster is more efficient and eco-
nomical than making multiple redundant measurements.
New markers should be examined to determine their corre-
lation with existing markers. If they belong to a cluster of
molecules that gives essentially the same information, they
are potentially redundant for disease monitoring.Acknowledgments
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It was of interest to isolate the cartilage contribution from
the bone contribution in HP. The very high rate of bone loss
in Paget’s disease should give an estimate of the ratio of
HP and LP from bone. Contributions of extra-osseous
tissue including cartilage to HP (eHP) could in principle be
obtained from total HP by subtraction of LP times a factor
() whose value is the ratio of HP to LP due to bone
catabolism alone. Thus eHP can be estimated as:
eHP/Creatinine=(HP−*LP)/Creatinine
In Paget’s disease, the HP/LP ratio is approximately 2.4.33
Thus eHP was estimated using =2.4 and the principal
components analysis was repeated with eHP/Cre instead
of HP/Cre. eHP is associated with markers of inflammation,
not bone metabolism. The composition of the other factors
remained essentially unchanged, although the factor con-
taining the remaining markers of bone metabolism, LP and
BSP, assumed less importance than in the first analysis.
The value of  in the calculation of eHP was estimated
independently, based on the factor analysis alone. Trial
values of  from 0.0 to 3.0, in steps of 0.1, were used to
calculate eHP, the factor analysis was repeated, and load-
ing coefficients for eHP in the inflammation (IL-6, etc.) and
bone (LP, BSP) principal components were examined. As 
approached 2.5, the correlation of eHP with bone markers
approached zero, and the loading coefficient of eHP
reached a maximum of 0.63 in its association with inflam-
mation markers. Values of  either smaller or larger than
2.5 decreased the independence of the separation. To
further confirm that eHP was correlated with the inflam-
mation markers, the correlation of CRP and eHP was
determined. eHP and CRP show a highly significant
correlation (P=0.01).
